Represented Teva Pharmaceuticals in Hatch-Waxman litigation involving seven Orange Book listed patents for the extended-release Alzheimer’s drug, Namenda XR®. Chris was part of a team that invalidated six patents, on indefiniteness grounds, prior to trial. Forest Labs., Inc. v. Teva Pharms. USA, Inc., C.A. No. 14-121, 2016 U.S. Dist. LEXIS 322 (D. Del. Jan. 5, 2016). Upon completion of a four-day bench trial on the remaining patent, the matter settled for value. (Prior to joining Robins Kaplan LLP.)
Represented Teva Pharmaceuticals in Hatch-Waxman litigation concerning OxyContin®. After an eight-day bench trial, the court found that each asserted patent was either not infringed and/or invalid. Purdue Pharma L.P. v. Teva Pharms., USA, Inc. (In re OxyContin Antitrust Litig.), 994 F. Supp. 2d 367 (S.D.N.Y. 2014). Chris and his team upheld this decision at the Federal Circuit. Purdue Pharma L.P. v. Epic Pharma, LLC, 811 F.3d 1345 (Fed. Cir.), cert. denied, 137 S. Ct. 475 (2016). (Prior to joining Robins Kaplan LLP.)
Represented Dynamic Air Ltda. in a patent infringement action concerning pneumatic conveying devices that transport oil rig drill cuttings. Chris was part of a team that argued that Dynamic Air—a Brazilian company—was not subject to personal jurisdiction in the District of Minnesota. M-I Drilling Fluids UK Ltd. V. Dynamic Air Ltda, Civil No. 13-2385, 2016 U.S. Dist. LEXIS 27357 (D. Minn. Mar. 1, 2016). (Prior to joining Robins Kaplan LLP.)
Represented Rust-Oleum in a trademark matter in the District of Minnesota. Was part of a team that defeated a motion for preliminary injunction. Plasti-Dip Int’l Inc. v. Rust-Oleum Brands Co., Civil No. 14-1831, 2014 U.S. Dist. LEXIS 174560 (D. Minn. Dec. 16, 2014). (Prior to joining Robins Kaplan LLP.)
Represented Breckenridge Pharmaceuticals in a Hatch-Waxman litigation relating to a cachexia drug, Megace ES®. Settled for value. Par Pharmaceuticals, Inc. v. Breckenridge Pharmaceutical, Inc. (Prior to joining Robins Kaplan LLP.)